Fig. 4From: Complexation with C60 Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In VitroViability of CCRF-CEM, Jurkat, THP1 and Molt16 leukemic cells, treated with equal doses of free Dox or C60-Dox complexes for 24, 48, and 72 h (*p ≤ 0.05 in comparison with the free Dox, **p ≤ 0.05 in comparison with the C60-Dox 1:1 complex, n = 5)Back to article page